Skip to search formSkip to main contentSkip to account menu

SB 743921

Known as: SB-743921, SB743921 
A synthetic small molecule with potential antineoplastic properties. SB-743921 selectively inhibits kinesin spindle protein (KSP), an important… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzamidesChromones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NP-.KAPPA.B signaling pathway
2012
2012
Mechanistic investigation of small molecule inhibitors of kinesin-5 and kinesin-6 family members in cancer drug development
The kinesins form a superfamily of molecular motors that use energy from ATP turnover to generate force. They carry out a diverse… 
2010
2010
The Novel Kinesin Spindle Protein Inhibitor SB-743921 Exhibits Marked Activity In In Vivo and In Vitro In Models of Aggressive Diffuse Large B-Cell Lymphoma
Abstract 118 A mitotic spindle target that has emerged as unique and potentially restricted to the mitotic spindle is Eg5, also… 
2009
2009
A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL).
8578 Background: KSP is a mitotic kinesin essential for cell cycle progression. SB-743921 (SB-921), a selective KSP inhibitor… 
2008
2008
A phase I-II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 on days 1 and 15 every 28 days in non-Hodgkin or Hodgkin lymphoma
2007
2007
A phase I-II study to assess the safety, pharmacokinetics, and potential efficacy of intravenous SB-743921 on days 1 and 15 of a 28-day cycle in patients with non-Hodgkin lymphoma
18516 Background: Kinesin spindle protein (KSP) is required for mitotic spindle bipolarity and cell cycle progression. SB-743921… 
2007
2007
A Phase I-II Study To Determine the Safety, Pharmacokinetics and Potential Efficacy of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 on Days 1 and 15 of a 28 Day Schedule in Patients with Non…
Background: KSP is required for mitotic spindle bipolarity and cell cycle progression. SB-743921 (SB-921) is a selective KSP… 
2006
2006
A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer
B11 Discovery and development of drugs that target mitosis continues to be an active and important area of cancer drug research… 
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the… 
2005
2005
Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor.
2000 Background: SB-743921, a potent and selective inhibitor of KSP (Ki =100 pM; >40,000-fold selectivity vs other kinesins… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)